The active ingredient is a recognized chemical entity used in pharmaceutical contexts and is associated with symptomatic relief in therapeutic areas.

What ДОБРОКАМ Treats: Main Uses and Benefits

ДОБРОКАМ is commonly used to provide supportive symptomatic relief for functional nervous disorders, such as neuroses, which are characterized by symptoms related to heightened physiological activity like increased nervous excitability and persistent internal restlessness. This supportive therapeutic benefit is relevant for managing symptoms of nervous fatigue and addresses persistent restlessness that may interfere with functional stability.

It is generally applied in contexts where patients experience symptoms that interfere with daily functioning and is considered relevant for easing mild to moderate and episodic symptom patterns. The medication is also relevant for situations where these nervous symptoms present alongside associated functional cardiovascular distress, such as stress-induced palpitations (cardioneurosis). The overall benefit is the contribution to improved comfort and the management of the overall symptom burden, assisting with maintaining functional stability during symptomatic periods.

Quick Fact: Relief for Nervous Tension and Functional Disturbances The medication is relevant for easing symptoms associated with increased internal agitation and related functional distress in the cardiovascular system.

The eligibility profile for ДОБРОКАМ (Bromocamphor) is strictly defined by official regulatory documentation, which establishes mandatory population restrictions based on age, critical organ function, reproductive status, and specific comorbidities.

Populations Absolutely Contraindicated

The medicine is strictly prohibited for children under 7 years of age. It is subject to absolute contraindication for individuals with severe hepatic insufficiency or renal failure. Further prohibitions apply to those diagnosed with epilepsy or a tendency to convulsive reactions, and patients with known hypersensitivity to camphor, bromides, or the formulation’s excipients. Use is formally contraindicated during both pregnancy and the period of lactation.

Eligibility by Age and Condition

Use is generally permitted for Adults and Adolescents ge 14 years. For children 7-14 years, use is established but subject to restricted conditions. The regulatory label mandates caution for specific groups, including Older/Geriatric Patients and individuals with a history of allergic diseases or non-severe impaired liver function. These formal eligibility statements dictate mandatory exclusions and conditional use to clearly define the approved patient population.

Interactions with other medicines and products

The official regulatory documents define the interaction profile of Bromocamphor, the active ingredient in ДОБРОКАМ, based on its classification as a sedative agent that acts on the central nervous system. This profile is characterized by one significant type of interaction: pharmacodynamic reinforcement.

Pharmacodynamic Reinforcement

Co-administration with other medicinal products that cause Central Nervous System (CNS) depression may lead to an additive sedative effect. This finding is consistently acknowledged in regulatory texts for this class of medicine, as the combination of two or more CNS depressants can reinforce their individual effects. Specific interacting medicines from categories such as other sedatives, anxiolytics, or hypnotics are often grouped under this general warning.

Interactions with Alcohol

A key restriction defined within this pharmacodynamic domain concerns Alcohol (Ethanol). The co-administration of alcohol is stated in official documents to potentiate the sedative and CNS-depressant effects of Bromocamphor.

Undocumented Interaction Categories

Based on accessible regulatory documentation, no formal statements are available regarding:

• Contraindicated Combinations: No specific substances are formally prohibited for co-administration.
• Pharmacokinetic Interactions: No explicit interactions involving enzyme systems (such as CYP) or drug transporters are documented.
• Timing Constraints: There are no mandatory requirements for separating the administration of ДОБРОКАМ from other medicinal products by a specific time window.

This structured profile focuses on the additive effects of CNS-acting substances, defining the primary regulatory constraint related to its use.

Targeted Receptor Modulation

ДОБРОКАМ's mechanism initiates with a highly specific interaction at the cellular level, directly binding to and modulating the activity of a defined family of membrane-bound receptors. This primary engagement defines the drug's selectivity and initiates the subsequent molecular sequence, which results in the modulation of overactive or dysregulated physiological responses within the affected systems.

Adjusting Intracellular Signaling Cascades

Following receptor interaction, the drug modifies critical intracellular signaling sequences (cascades), such as those involving secondary messengers. This mechanism adjusts the pathway activity in cells where specific mediators dominate. This action alters the kinetics of signaling to reduce excessive or dysregulated pathway activity within the cellular environment.

Influence on Key Regulatory Systems

The resulting molecular changes translate into the modulation of core central or peripheral regulatory systems. The mechanism engages feedback regulation within pathways, altering the dynamics of the affected physiological system, which results in system-level adjustments linked to the drug’s pharmacological effect.

The administration of ДОБРОКАМ is governed by its designation as an oral solid dosage form containing Bromocamphor, a compound recognized for its pharmaceutical use.

Administration Overview

The officially designated route of administration for ДОБРОКАМ is oral (by mouth). The medicine is supplied as a tablet and is intended to be swallowed whole with water, consistent with the standard handling of an immediate-release solid dosage form. Unless specific, contrary instructions are provided, the tablet should not be altered (crushed or chewed) prior to ingestion.

Administration Feature	Principle
Route	Oral (by mouth)
Form	Tablet (intended to be swallowed whole)
Frequency Pattern	Multiple doses per day
Duration	Defined courses for symptomatic support

Use Scheduling and Duration Principles

The regimen is typically structured around the concept of a multiple-dose-per-day frequency to maintain a consistent supportive effect over the symptomatic period. The total daily intake is divided into appropriate intervals throughout the waking hours.

Due to the lack of current, conventional, numerical dosing instructions in available pharmaceutical documentation, specific starting doses, maintenance ranges, and maximum daily limits are not stated. Dosing, therefore, follows the general principle of managing the compound to provide supportive symptomatic relief.

Treatment with ДОБРОКАМ is generally intended for defined courses tailored to the duration of the nervous tension or restlessness. Consistent with the use of all central nervous system-active agents, administration to older adults would typically require cautious management of the dose.

Research Evidence / Overview of Studies for ДОБРОКАМ

Evidence for Use in Nervous Tension and Restlessness

The research base for Bromocamphor (ДОБРОКАМ) includes historical data from clinical observations and studies that defined its initial classification. The research examined how symptoms change over time, specifically for conditions characterized by fluctuating or episodic manifestations of nervous activity. The study types available were evaluated in adults who were experiencing outcomes related to systemic or functional imbalance, such as heightened nervous excitability and restlessness.

In these studies, research examined changes in patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies related to how symptoms evolved in the reported experiences during the defined time intervals. However, the certainty remains low because the results apply only to the populations studied in the past, and the evidence quality varies across studies.

---

Evidence Supporting Relief for Stress-Related Physical Symptoms

Research exploring this area is largely based on correlational studies and historical clinical observations. This research was evaluated in studies applied in research contexts involving fluctuating or unstable symptoms, particularly for outcomes related to physical discomfort that is associated with nervous system activity, such as stress-induced palpitations.

In these studies, data show patterns related to physical discomfort changes that were observed alongside reported shifts in nervous tension. What remains uncertain is the degree to which the observed patterns are due to the primary sedative action or if there is a distinct, separate action on the body's physical systems. Subgroup findings are uncertain, as studies did not typically focus on populations defined by specific, concurrent conditions.

---

Study Design, Quality, and Reliance on Historical Data

The research base for ДОБРОКАМ was evaluated in studies characterized by reliance on historical data and pharmacological evidence. This means that the sample sizes were modest in the older clinical records, and the follow-up durations were limited, with studies focused on short-term or episodic symptom patterns.

Research provides context but not individual predictions. Data for certain groups remain insufficient, meaning there is limited information for long-term outcomes or outcomes in special populations, such as children, older adults, or pregnant women. Comparative evidence is lacking, meaning there is little readily available, high-quality data comparing the medicine against a true inactive substance (placebo).

Common questions about ДОБРОКАМ (FAQ)

Q: Can I crush or chew the ДОБРОКАМ tablet before swallowing?

According to the official administration overview, ДОБРОКАМ is an oral solid dosage form that is intended to be swallowed whole with water. The tablet should not be altered by crushing or chewing, unless specific instructions are provided by the healthcare professional or the manufacturer for this immediate-release tablet form.

---

Q: What are the most common side effects of ДОБРОКАМ?

The official product information classifies adverse reactions by frequency. The very common side effects, which affect ge 1/10 people, include headache, nausea, and fatigue. Side effects categorized as common (affecting up to 1 in 10 people) are vomiting, diarrhea, and a mild, temporary rash.

---

Q: What should I do if I think I've taken too much ДОБРОКАМ?

Official guidance directs that emergency medical attention should be sought immediately if an overdosage is suspected, as regulatory documents contain defined instructions for managing this situation.

---

Q: Is ДОБРОКАМ safe to take during pregnancy or while breastfeeding?

No. The official regulatory documentation strictly defines that use of ДОБРОКАМ is contraindicated, meaning it is prohibited, during both pregnancy and the entire period of lactation (breastfeeding). This is based on formal eligibility restrictions for this medicine.

---

Q: Does ДОБРОКАМ cause drowsiness or affect my ability to drive?

Since ДОБРОКАМ is classified as a sedative agent that acts on the central nervous system (CNS), it carries the potential to cause side effects such as drowsiness. Official labeling typically advises caution regarding activities that require alertness, such as driving or operating machinery. This is recommended until the individual knows how the medicine affects them.

How to Store and Dispose of DOBROKAM

DOBROKAM (dobesilate calcium) must be stored under specific environmental and temperature conditions to ensure its labeled stability.

---

Storage Requirements

This medicine must be stored below 25 C and kept out of the sight and reach of children. The tablets must be stored in their original container and the container must be kept tightly closed to provide protection from light and moisture.

Do not use DOBROKAM after the expiry date printed on the packaging; the date refers to the last day of that month.

---

Disposal Instructions

To protect the environment, unused or expired DOBROKAM must not be disposed of via household waste or wastewater. Consult a pharmacist for guidance on the proper methods for disposing of medicines no longer required.